PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors
On September 8, 2022, PolarityTE (Nasdaq: PTE) announced the immediate resignation of Jeff Dyer, PhD, from its Board of Directors. Dyer thanked the management for their efforts in advancing PolarityTE's IND application for SkinTE® and clinical trial processes. CEO Richard Hague acknowledged Dyer's contributions over the past five and a half years, particularly in securing FDA acceptance for SkinTE® and initiating a clinical trial for diabetic foot ulcers. The company continues to pursue pivotal studies for SkinTE® required for a biologics license application.
- Dyer's resignation allows for potential fresh perspectives in leadership.
- Continued progress on SkinTE® with FDA acceptance indicates strong regulatory path.
- Loss of Dyer may create continuity concerns within the Board.
- Potential experience gap following Dyer's departure could impact strategic decisions.
SALT LAKE CITY, Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately.
"On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague, Chief Executive Officer of PolarityTE. "We greatly appreciate the leadership and insight that Jeff has provided over the past five and a half years as we pursued the path that led to an IND accepted by FDA for our product SkinTE® and the start of an approved clinical trial in diabetic foot ulcers."
Dr. Dyer stated, "It has been an honor to serve as a director of PolarityTE. Richard and his team have done an incredible job advancing PolarityTE's IND application and clinical trial process. Now that PolarityTE has settled into a well-defined regulatory path and clinical trial process for SkinTE®, I believe my time and talents may be better applied in other opportunities and endeavors." Dr. Dyer went on to say, "I want to thank my fellow directors and wish the Company nothing but success."
About PolarityTE®
PolarityTE, Inc., headquartered in Salt Lake City, Utah, is a biotechnology company developing regenerative tissue products. PolarityTE's first regenerative tissue product is SkinTE®. PolarityTE has an open investigational new drug application (IND) for SkinTE® with the U.S. Food and Drug Administration (FDA) and is now pursuing the first of two pivotal studies on SkinTE® needed to support a biologics license application (BLA). SkinTE® is available for investigational use only. Learn more at www.PolarityTE.com.
Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to the impact of the COVID-19 pandemic, future clinical studies, and FDA regulatory matters, which cannot be predicted, and the risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are registered trademarks of PolarityTE, Inc.
CONTACTS
Investors:
PolarityTE Investor Relations
ir@PolarityTE.com
385-831-5284
Media:
David Schull or Ignacio Guerrero-Ros
David.schull@russopartnersllc.com
Ignacio.guerrero-ros@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/polarityte-announces-resignation-of-jeff-dyer-from-its-board-of-directors-301619900.html
SOURCE PolarityTE, Inc.
FAQ
Why did Jeff Dyer resign from PolarityTE's Board of Directors?
What impact might Jeff Dyer's resignation have on PolarityTE?
What are PolarityTE's plans for SkinTE® following Dyer's resignation?
When was the resignation of Jeff Dyer from PolarityTE announced?
